(UroToday.com) In this presentation, Dr. de Bono summarized results of the IPATential150 trial, previously presented at ESMO 2020, which demonstrated an rPFS benefit for the combination of the AKT-inhibitor ipatasertib with abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC). This benefit was seen in the intention to treat population as well as when patients were stratified by PTEN expression status as defined by immunohistochemistry. PTEN loss was defined as more than 50% of viable malignant cells having no PTEN cytoplasmic staining using the SP218 PTEN immunohistochemistry antibody. The study design is summarized below.